<DOC>
	<DOCNO>NCT01677468</DOCNO>
	<brief_summary>The aim study evaluate whether survival patient underwent TACE unresectable HCC benefit intermediate-levels embolization .</brief_summary>
	<brief_title>Survival According Feeding Artery Obliteration Chemoembolization Unresectable Hepatocellular Carcinoma</brief_title>
	<detailed_description>Subjective angiographic chemoembolization endpoint ( SACE ) level develop standardize embolic endpoint transarterial chemoembolization ( TACE ) hepatocellular carcinoma ( HCC ) . It determine antegrade arterial flow residual tumor blush follow : I , normal-normal ; II , reduced-reduced ; III , reduced-none ; IV , none-none . SACE level II III indicate intermediate-levels embolization , whereas IV indicate overembolization . The aim study evaluate whether survival patient underwent TACE unresectable HCC benefit intermediate-levels embolization .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Gelatin Sponge , Absorbable</mesh_term>
	<criteria>age 18 ECOG performance status 02 Hepatocellular carcinoma diagnose histologically clinically Tumor number 5 less No history treatment hepatocellular carcinoma Patients informed consent Extrahepatic metastasis Rupture hepatocellular carcinoma Infiltrative hepatocellular carcinoma Malignancy hepatocellular carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>Transarterial chemoembolization</keyword>
</DOC>